https://www.cancer.gov/news-events/cancer-currents-blog/2017/blinatumomab-leukemia?cid=eb_govdel
A Cancer Currents blog post on a large clinical trial showing that blinatumomab improves survival and causes fewer side effects than standard chemotherapy.
blinatumomabimprovessurvivaladvancednci
https://www.cancer.gov/news-events/cancer-currents-blog/2021/blinatumomab-relapsed-b-cell-leukemia-children-young-adults
The immunotherapy drug blinatumomab (Blincyto) is more effective than chemotherapy in treating B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed in...
for childrenblinatumomabeffectiverelapsedleukemia
https://www.ajmc.com/view/blinatumomab-significantly-improves-os-in-newly-diagnosed-b-all-patients-who-are-mrd-negative-after-initial-treatment
Consolidation therapy with blinatumomab significantly improves overall survival (OS) in adult patients newly diagnosed with B-cell acute lymphoblastic leukemia...
blinatumomabimprovesosnewlypatients